Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 15/20 | 1.00 |
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527973 | 1.00 | CETP (1.00) | CETPMMEMDM4TP53 | |
| SCHEMBL18602182 | 1.00 | CETP (1.00) | CETPMMEMDM4TP53 | |
| Hydrogen Sulfide SCHEMBL28096222 | 0.99 | CETP (0.97) | CETPMMEMDM4TP53 | |
| SCHEMBL9943229 | 0.93 | CETP (0.87) | CETPMMEMDM4TP53 | |
| SCHEMBL14408429 | 0.87 | CETP (0.77) | CETPTP53 | |
| SCHEMBL21252687 | 0.87 | CETP (0.76) | CETPMME | |
| SCHEMBL2490285 | 0.87 | CETP (0.77) | CETPMME | |
| SCHEMBL528151 | 0.87 | CETP (0.77) | CETPMMEMDM4TP53 | |
| SCHEMBL529244 | 0.87 | CETP (1.00) | CETPMMEMDM4TP53 | |
| SCHEMBL1534085 | 0.86 | CETP (0.76) | CETPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NEUROBO PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12371748-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | HOFFMANN-LA ROCHE INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-111073974-B | Genetic markers for predicting responsiveness to treatment | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11549142-B2 | CETP inhibitors for therapeutic use | HOFFMANN-LA ROCHE INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS INC (US) | 2022-10-20 | — | — | US | disclosed |
| US-11401554-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | HOFFMAN-LA ROCHE INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114381512-A | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agents | 豪夫迈·罗氏有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-106559998-B | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agents | 豪夫迈·罗氏有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NPC1L1, NOTUM, CEL | CETP 39/4885MME 3617/4885MDM4 3134/4885 |
| US-11549142-B2 | CETP inhibitors for therapeutic use | CETP, HDLBP, APOB | CETP 1/4885MME 377/4885MDM4 3655/4885 |
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | CETP, HDLBP, APOB | CETP 1/4885MME 581/4885MDM4 2741/4885 |
| US-12371748-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | CETP, HDLBP, APOB | CETP 1/4885MME 575/4885MDM4 2865/4885 |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NPC1L1, NOTUM, CEL | CETP 39/4885MME 3617/4885MDM4 3134/4885 |
| US-11401554-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | CETP, HDLBP, APOB | CETP 1/4885MME 575/4885MDM4 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.